

**AMENDMENTS TO THE CLAIMS**

Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

1. **(Previously Presented)** A method of treating an angiodependent disease, comprising administering 2,5-dihydroxybenzenesulfonic acid or of any of its pharmaceutically acceptable salts to an individual in need thereof.
2. **(Previously Presented)** The method of claim 1, in which the angiodependent disease also presents a reduction of apoptosis.
3. **(Cancelled)**
4. **(Cancelled)**
5. **(Previously Presented)** The method of claim 1, wherein the pharmaceutically acceptable salt is the potassium salt of the 2,5-dihydroxybenzene sulfonic acid.
6. **(Previously Presented)** The method of claim 1, wherein the pharmaceutically acceptable salt is the calcium salt of the 2,5-dihydroxybenzene sulfonic acid.
7. **(Previously Presented)** The method of claim 1, wherein the 2,5-dihydroxybenzenesulfonic acid compound is formulated with at least one pharmaceutically acceptable excipient.
- 8-11. **(Cancelled)**
12. **(Previously Presented)** The method of claim 1, wherein the 2,5-dihydroxybenzenesulfonic acid compound is formulated for topical administration.
13. **(Previously Presented)** The method of claim 12, wherein the 2,5-

dihydroxybenzenesulfonic acid compound is formulated as a cream or unguent whose composition includes:

A pharmaceutically efficient amount of the 2,5-dihydroxybenzenesulfonic acid or of any of its pharmaceutically acceptable salts;

A pharmaceutically acceptable amount of at least one alcohol;

A pharmaceutically acceptable amount of at least one emulsifier;

A pharmaceutically acceptable amount of at least one excipient;

A pharmaceutically acceptable amount of at least one excipient comprising a lipid phase; and

Distilled water.

14. **(Previously Presented)** The method of claim 13, wherein the cream or unguent comprises:

5% of the potassium salt of the 2,5-dihydroxybenzenesulfonic acid;

2.5% of cetyllic alcohol;

2.5% of stearic alcohol;

30% of liquid Vaseline;

30% of white soft paraffin;

5% span (sorbitan oleate); and

q.s 100 g of distilled water.

15. **(New)** The method of claim 1, wherein the angiodependent disease is psoriasis.

16. **(New)** The method of claim 2, wherein the angiodependent disease is psoriasis.